MAFA
SUPN icon

MJT & Associates Financial Advisory’s Supernus Pharmaceuticals SUPN Stock Holding History

MJT & Associates Financial Advisory’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-54
Closed -$1.7K – 506
2025
Q2 		$1.7K Hold
54
– – ﹤0.01% 408
2025
Q1 		$1.77K Buy
+54
New +$1.91K ﹤0.01% 406

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MJT & Associates Financial Advisory's SUPN Position: Q3 2025 in Review

MJT & Associates Financial Advisory sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 54 shares — an estimated $1.7K sold.

MJT & Associates Financial Advisory first reported a position in SUPN in Q1 2025 and held it in 2 quarters. The position peaked at $1.77K in Q1 2025. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • MJT & Associates Financial Advisory reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • MJT & Associates Financial Advisory sold 54 Supernus Pharmaceuticals shares in Q3 2025, an estimated $1.7K.
  • MJT & Associates Financial Advisory first reported a position in Supernus Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • MJT & Associates Financial Advisory's Supernus Pharmaceuticals position peaked at $1.77K in Q1 2025.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on MJT & Associates Financial Advisory's 13F filing for Q3 2025, filed 15 Oct 2025.